Ardelyx, Inc. (ARDX)
| Market Cap | 776.74M -47.1% |
| Revenue (ttm) | 468.22M +17.6% |
| Net Income | -55.47M |
| EPS | -0.22 |
| Shares Out | 251.37M |
| PE Ratio | n/a |
| Forward PE | 74.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,380,472 |
| Open | 3.140 |
| Previous Close | 3.120 |
| Day's Range | 3.050 - 3.150 |
| 52-Week Range | 2.800 - 8.400 |
| Beta | 0.77 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+304.53%) |
| Earnings Date | Nov 3, 2026 |
About ARDX
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an... [Read more]
Financial Performance
In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 304.53% from the latest price.
News
Shareholders Sue Ardelyx (ARDX) over Bowel Drug Revenue Claims
A class action lawsuit was filed against Ardelyx ($ARDX) on September 17, 2026. Plaintiffs in the federal securities lawsuit allege that they acquired Ardelyx stock at artificially inflated prices bet...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 16, 2026 in Ardelyx, Inc. Lawsuit - ARDX
Ardelyx's Chief Commercial Officer, Eric Foster, is named as an individual defendant in a securities class action alleging he assured investors the Company's patient-access strategy was working while ...
Ardelyx price target lowered to $11 from $14 at BTIG
BTIG lowered the firm’s price target on Ardelyx (ARDX) to $11 from $14 and keeps a Buy rating on the shares after hosting its management team following the company’s Q3…
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
WALTHAM, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines tha...
Ardelyx Earnings Call Transcript: Q3 2026
Q3 product revenue rose 19% YoY to $125.5M, with IBSRELA leading growth; net loss narrowed to $0.7M. FY 2026 product and expense guidance was reaffirmed, with profitability still targeted for 2027.
Ardelyx Earnings release: Q3 2026
Ardelyx released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Ardelyx Quarterly report: Q3 2026
Ardelyx has published its Q3 2026 quarterly earnings report on November 3, 2026.
Ardelyx Slides: Q3 2026
Ardelyx has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Ardelyx reports Q3 EPS 0c, consensus (2c)
Reports Q3 revenue $127.66M, consensus $128M. “Our third quarter results reflect the strength of the foundation we’ve built,” said Mike Raab, President and Chief Executive Officer of Ardelyx (ARDX). “...
Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update
Q3 2026 total product revenue of $125.5 million , reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with $285.3 milli...
Ardelyx completes enrollment in ACCEL clinical trial
Ardelyx (ARDX) announced that it has fully enrolled ahead of schedule all patients in the Phase 3 ACCEL clinical trial evaluating the safety and efficacy of Ibsrela for the treatment…
Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation
Trial fully enrolled ahead of schedule Topline data expected in the second half of 2027 WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a c...
Kaplan Fox Alerts Ardelyx, Inc. (ARDX) Investors to an Approaching Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: A...
Ardelyx management to meet virtually with BTIG
Virtual Meeting to be held on November 4 hosted by BTIG.
Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 23, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: A...
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluated
Kaplan Fox Urges Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: A...
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercializatio...
Kaplan Fox Encourages Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026 for a Leadership Role
New York, New York--(Newsfile Corp. - October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: A...
ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired A...
Kaplan Fox Advises Ardelyx, Inc. (ARDX) Investors to Act Before the Lead Plaintiff Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 13, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: A...
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes Presentations include real-world XPHOZAH® (tenapanor) data and new insights i...
Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 16, 2026
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: AR...
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ardelyx, Inc. (ARDX)
Philadelphia, Pennsylvania--(Newsfile Corp. - October 1, 2026) - What is The Investigation About? Grabar Law Office is investigating whether certain officers and directors of Ardelyx, Inc. (NYSE: ARDX...
Robbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two Core Drug Products
San Diego, California--(Newsfile Corp. - September 30, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased o...